Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Akebia Therapeutics	Wave Life Sciences	Avadel Pharmaceuticals	89bio	Marinus Pharmaceuticals
Symbol	NASDAQ:AKBA	NASDAQ:WVE	NASDAQ:AVDL	NASDAQ:ETNB	NASDAQ:MRNS
Price Information
Current Price	$2.97	$6.11	$8.49	$28.00	$14.16
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.8	1.8	1.5	1.6	1.7
Analysis Score	3.3	3.3	3.5	3.6	3.5
Community Score	2.7	2.6	2.4	2.9	2.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	2.5	0.8	1.7	1.7
Earnings & Valuation Score	1.3	0.6	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$9.63	$11.80	$18.60	$61.88	$28.75
% Upside from Price Target	224.07% upside	93.13% upside	119.08% upside	120.98% upside	103.04% upside
Trade Information
Market Cap	$434.41 million	$299.37 million	$478.24 million	$517.10 million	$518.72 million
Beta	2.11	0.35	1.55	N/A	1.72
Average Volume	6,110,728	820,890	470,263	151,231	324,003
Sales & Book Value
Annual Revenue	$335 million	$15.98 million	$59.22 million	N/A	N/A
Price / Sales	1.36	18.73	8.38	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$3.32 per share	$1.86 per share	($0.78) per share	$6.92 per share	$2.90 per share
Price / Book	0.89	3.28	-10.88	N/A	N/A
Profitability
Net Income	$-279,660,000.00	$-193,640,000.00	$-33,230,000.00	$-57,420,000.00	$-54,120,000.00
EPS	($1.63)	($5.72)	($0.89)	($24.49)	($3.96)
Trailing P/E Ratio	N/A	N/A	42.45	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-126.86%	-1,562.01%	38.70%	N/A	N/A
Return on Equity (ROE)	-68.51%	-401.32%	-33.91%	-49.56%	-95.56%
Return on Assets (ROA)	-34.01%	-72.82%	-11.75%	-46.52%	-66.01%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.24%	N/A	0.74%	N/A	N/A
Current Ratio	2.15%	1.33%	12.24%	23.61%	10.08%
Quick Ratio	1.67%	1.33%	12.24%	23.61%	10.08%
Ownership Information
Institutional Ownership Percentage	68.98%	80.67%	53.78%	80.63%	79.32%
Insider Ownership Percentage	2.55%	38.20%	1.41%	18.10%	2.80%
Miscellaneous
Employees	379	301	32	25	65
Shares Outstanding	153.50 million	49.00 million	58.47 million	20.04 million	36.63 million
Next Earnings Date	5/4/2021 (Estimated)	5/10/2021 (Estimated)	5/10/2021 (Estimated)	5/12/2021 (Estimated)	5/3/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Marinus Pharmaceuticals Inc (MRNS) investing.com - April 18 at 10:55 PM
	If You Had Bought Marinus Pharmaceuticals (NASDAQ:MRNS) Stock A Year Ago, You Could Pocket A 101% Gain Today finance.yahoo.com - April 16 at 1:21 PM
	Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com - April 12 at 6:21 PM
	Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Gap Down to $15.52 americanbankingnews.com - April 12 at 11:30 AM
	Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments finance.yahoo.com - April 12 at 8:21 AM
	Marinus Pharmaceuticals (NASDAQ:MRNS) Trading Up 3.1% americanbankingnews.com - April 9 at 12:32 PM
	Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Rating of "Buy" by Brokerages americanbankingnews.com - April 4 at 6:22 AM
	Marinus (MRNS) Gets a Buy Rating from Leerink Partners smarteranalyst.com - March 11 at 12:25 PM
	Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates finance.yahoo.com - March 9 at 2:28 PM
	Marinus Pharmaceuticals: Q4 Earnings Snapshot apnews.com - March 9 at 9:27 AM
	Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization finance.yahoo.com - February 23 at 8:06 AM
	Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences markets.businessinsider.com - February 17 at 7:03 AM
	What Kind Of Shareholders Own Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)? finance.yahoo.com - February 15 at 9:34 AM
$Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus$	Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus finance.yahoo.com - January 26 at 9:49 AM
	MRNS Feb 2021 14.000 call in.finance.yahoo.com - January 23 at 6:32 PM
	MRNS Feb 2021 16.000 call in.finance.yahoo.com - January 20 at 5:23 PM
	MRNS Feb 2021 11.000 put in.finance.yahoo.com - January 20 at 5:23 PM
	Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in ... businesswire.com - January 13 at 11:05 PM
	Stock Alert: Marinus Pharmaceuticals Climbs 11% nasdaq.com - January 13 at 1:04 PM
	Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD) finance.yahoo.com - January 13 at 8:01 AM
	MRNS Jan 2021 8.000 put ca.finance.yahoo.com - January 7 at 12:30 AM
	Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference finance.yahoo.com - January 6 at 9:29 AM
	5 Disruptive Biotech Stocks With Solid Long-Term Potential finance.yahoo.com - January 4 at 12:58 PM
	MRNS Jan 2021 17.000 put in.finance.yahoo.com - December 23 at 10:52 PM
	MRNS Jan 2021 10.000 put uk.finance.yahoo.com - December 23 at 12:58 AM

Date	Company	Brokerage	Action
3/15/2021	Akebia Therapeutics	HC Wainwright	Lower Price Target
3/15/2021	Akebia Therapeutics	Cantor Fitzgerald	Initiated Coverage
1/29/2021	Akebia Therapeutics	JPMorgan Chase & Co.	Downgrade
9/4/2020	Akebia Therapeutics	Morgan Stanley	Lower Price Target
9/4/2020	Akebia Therapeutics	BTIG Research	Lower Price Target
9/4/2020	Akebia Therapeutics	Mizuho	Lower Price Target
8/11/2020	Akebia Therapeutics	Needham & Company LLC	Initiated Coverage
5/6/2020	Akebia Therapeutics	Royal Bank of Canada	Boost Price Target
3/30/2021	Wave Life Sciences	Truist	Lower Price Target
3/30/2021	Wave Life Sciences	SVB Leerink	Lower Price Target
12/31/2019	Wave Life Sciences	SunTrust Banks	Reiterated Rating
12/17/2019	Wave Life Sciences	Guggenheim	Lower Price Target
12/16/2019	Wave Life Sciences	Cowen	Reiterated Rating
11/9/2020	Avadel Pharmaceuticals	Lifesci Capital	Reiterated Rating
8/11/2020	Avadel Pharmaceuticals	Ci Capital	Reiterated Rating
7/30/2020	Avadel Pharmaceuticals	Oppenheimer	Initiated Coverage
5/4/2020	Avadel Pharmaceuticals	Piper Sandler	Boost Price Target
4/3/2020	Avadel Pharmaceuticals	Craig Hallum	Boost Price Target
4/3/2020	Avadel Pharmaceuticals	Jefferies Financial Group	Initiated Coverage
3/12/2020	Avadel Pharmaceuticals	Stifel Nicolaus	Initiated Coverage
9/24/2019	Avadel Pharmaceuticals	Laidlaw	Boost Price Target
6/14/2019	Avadel Pharmaceuticals	LADENBURG THALM/SH SH	Upgrade
8/7/2018	Avadel Pharmaceuticals	JMP Securities	Downgrade
3/25/2021	89bio	Chardan Capital	Boost Price Target
10/19/2020	89bio	Raymond James	Initiated Coverage
9/25/2020	89bio	Bank of America	Upgrade

(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources